ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like How Bristol-Myers Squibb Went From Potential Mega-Acquirer to Vulnerable Mega-Target January 26, 2017 Massachusetts' Inotek Exploring Strategic Alternatives After Another Glaucoma Trial Failure July 9, 2017 InstantLabs Secures Controlling Investment From February 23, 2017
How Bristol-Myers Squibb Went From Potential Mega-Acquirer to Vulnerable Mega-Target January 26, 2017
Massachusetts' Inotek Exploring Strategic Alternatives After Another Glaucoma Trial Failure July 9, 2017
